Cost of Revenue Comparison: Pfizer Inc. vs CRISPR Therapeutics AG

Cost of Revenue: A Tale of Two Biotech Giants

In the ever-evolving landscape of biotechnology, Pfizer Inc. and CRISPR Therapeutics AG stand as titans with distinct trajectories. From 2014 to 2023, Pfizer's cost of revenue surged by over 200%, peaking in 2022 with a staggering $34.3 billion. This reflects Pfizer's expansive operations and its pivotal role in global healthcare, especially during the COVID-19 pandemic.

Conversely, CRISPR Therapeutics AG, a pioneer in gene-editing technology, exhibited a more modest growth. Starting with a cost of revenue of just $1.5 million in 2014, it reached $130 million by 2023, marking an impressive 8,500% increase. This underscores CRISPR's rapid innovation and scaling efforts in a competitive market.

While Pfizer's financial might is evident, CRISPR's exponential growth highlights the disruptive potential of emerging biotech firms. As these companies continue to innovate, their financial strategies will be crucial in shaping the future of medicine.